Stacey L. Hembruff

1.1k total citations
23 papers, 890 citations indexed

About

Stacey L. Hembruff is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Stacey L. Hembruff has authored 23 papers receiving a total of 890 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 11 papers in Oncology and 6 papers in Cell Biology. Recurrent topics in Stacey L. Hembruff's work include Drug Transport and Resistance Mechanisms (6 papers), Microtubule and mitosis dynamics (4 papers) and Protein Degradation and Inhibitors (3 papers). Stacey L. Hembruff is often cited by papers focused on Drug Transport and Resistance Mechanisms (6 papers), Microtubule and mitosis dynamics (4 papers) and Protein Degradation and Inhibitors (3 papers). Stacey L. Hembruff collaborates with scholars based in United States and Canada. Stacey L. Hembruff's co-authors include Amadeo M. Parissenti, David J. Villeneuve, Nikki Cheng, Zachary Veitch, Baoqing Guo, Kapil N. Bhalla, Warren Fiskus, Rekha Rao, Ramesh Balusu and Li Yang and has published in prestigious journals such as Blood, Cancer Research and Analytical Biochemistry.

In The Last Decade

Stacey L. Hembruff

22 papers receiving 873 citations

Peers

Stacey L. Hembruff

ONCOL

IMMUN

Eftihia Cocolakis Canada

Mayuko Omori United States

Banibrata Sen United States

Marco Cirò Italy

Paolo Bonvini Italy

Chris Proffitt United States

Christian Borgo Italy

Vishal Pendharkar Singapore

Troii Hall United States

Murray J. Towle United States

Eftihia Cocolakis Canada

Stacey L. Hembruff

898 ×1.5

342 ×1.0

ONCOL

120 ×0.8

69 ×0.6

123 ×1.2

IMMUN

Citations per year, relative to Stacey L. Hembruff Stacey L. Hembruff (= 1×) peers Eftihia Cocolakis

Countries citing papers authored by Stacey L. Hembruff

Since Specialization

Citations

This map shows the geographic impact of Stacey L. Hembruff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacey L. Hembruff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacey L. Hembruff more than expected).

Fields of papers citing papers by Stacey L. Hembruff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stacey L. Hembruff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacey L. Hembruff. The network helps show where Stacey L. Hembruff may publish in the future.

Co-authorship network of co-authors of Stacey L. Hembruff

This figure shows the co-authorship network connecting the top 25 collaborators of Stacey L. Hembruff. A scholar is included among the top collaborators of Stacey L. Hembruff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stacey L. Hembruff. Stacey L. Hembruff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hembruff, Stacey L., Alexander Dekonenko, John P. Thyfault, et al.. (2025). BRCA1 influences whole body metabolism in humanized mice. American Journal of Physiology-Endocrinology and Metabolism. 328(6). E979–E993.

Turaga, Soumya M., et al.. (2023). Inducing Mitotic Catastrophe as a Therapeutic Approach to Improve Outcomes in Ewing Sarcoma. Cancers. 15(20). 4911–4911. 3 indexed citations

Fiskus, Warren, Rekha Rao, Ramesh Balusu, et al.. (2012). Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells. Clinical Cancer Research. 18(22). 6227–6238. 40 indexed citations

Rao, Rekha, Ramesh Balusu, Warren Fiskus, et al.. (2012). Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells. Molecular Cancer Therapeutics. 11(4). 973–983. 96 indexed citations

Sprowl, Jason A., Stephen Armstrong, Carita Lannér, et al.. (2012). Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells. Breast Cancer Research. 14(1). R2–R2. 56 indexed citations

Fiskus, Warren, Stacey L. Hembruff, Rekha Rao, et al.. (2012). Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. Breast Cancer Research and Treatment. 135(2). 433–444. 27 indexed citations

Fiskus, Warren, Srđan Verstovšek, Taghi Manshouri, et al.. (2011). Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells. Clinical Cancer Research. 17(23). 7347–7358. 83 indexed citations

Morales, Pedro Jorge Cortes, Xiaoying Zhang, Stacey L. Hembruff, et al.. (2011). Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer. 11(1). 468–468. 75 indexed citations

Fiskus, Warren, Jacqueline Smith, Uma Mudunuru, et al.. (2011). Abstract C144: Treatment with β-catenin antagonist BC2059 exhibits single agent efficacy and exerts superior activity with tyrosine kinase inhibitor (TKI) or histone deacetylase (HDAC) inhibitor against human AML, CML, and myeloproliferative neoplasm (MPN) progenitor cells.. Molecular Cancer Therapeutics. 10(11_Supplement). C144–C144. 3 indexed citations

10.

Reed, Kate, Stacey L. Hembruff, Jason A. Sprowl, & Amadeo M. Parissenti. (2010). The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance. The Pharmacogenomics Journal. 10(6). 489–504. 40 indexed citations

11.

Veitch, Zachary, Baoqing Guo, Stacey L. Hembruff, et al.. (2009). Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenetics and Genomics. 19(6). 477–488. 44 indexed citations

12.

Hembruff, Stacey L. & Nikki Cheng. (2009). Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting.. PubMed. 7(A). 254–267. 53 indexed citations

13.

Hembruff, Stacey L., et al.. (2008). Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance. BMC Cancer. 8(1). 318–318. 66 indexed citations

14.

Hembruff, Stacey L., et al.. (2008). Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells. Epigenetics. 3(5). 270–280. 44 indexed citations

15.

Sprowl, Jason A., et al.. (2007). Changes in expression of cell wall turnover genes accompany inhibition of chromosome segregation by bovine protein kinase C α expression in Saccharomyces cerevisiae. Cell Biology International. 31(10). 1160–1172. 5 indexed citations

16.

Parissenti, Amadeo M., et al.. (2007). Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells. Anti-Cancer Drugs. 18(5). 499–523. 14 indexed citations

17.

Hembruff, Stacey L., David J. Villeneuve, & Amadeo M. Parissenti. (2005). The optimization of quantitative reverse transcription PCR for verification of cDNA microarray data. Analytical Biochemistry. 345(2). 237–249. 32 indexed citations

18.

Villeneuve, David J., et al.. (2005). cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Research and Treatment. 96(1). 17–39. 45 indexed citations

19.

Guo, Baoqing, et al.. (2004). Cross-Resistance Studies of Isogenic Drug-Resistant Breast Tumor Cell Lines Support Recent Clinical Evidence Suggesting that Sensitivity to Paclitaxel may be Strongly Compromised by Prior Doxorubicin Exposure. Breast Cancer Research and Treatment. 85(1). 31–51. 57 indexed citations

20.

Guo, Baoqing, et al.. (2003). Potent Killing of Paclitaxel- and Doxorubicin-resistant Breast Cancer Cells by Calphostin C Accompanied by Cytoplasmic Vacuolization. Breast Cancer Research and Treatment. 82(2). 125–141. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact